Key Laboratory of Experimental Marine Biology, Institute of Oceanology, Chinese Academy of Sciences, Qingdao, China.
Laboratory for Marine Drugs & Bioproducts, Qingdao National Laboratory for Marine Science & Technology, Qingdao, China.
Nanomedicine (Lond). 2018 Jun;13(11):1303-1318. doi: 10.2217/nnm-2017-0359.
To assess the effect of zinc-doped copper oxide nanocomposites (nZn-CuO NPs) on glioblastoma therapy.
MATERIALS & METHODS: nZn-CuO NPs were synthesized by sonochemical method and its antitumor effects and underlying molecular mechanisms were investigated both in vitro and in vivo.
After nZn-CuO NPs treatment, cell proliferation was significantly inhibited in dividing cancer cells but less toxicity was observed in normal cells. In vivo studies show that nZn-CuO NPs inhibited tumor growth in a dose-dependent manner. Further study found that nZn-CuO NPs trigger cell reactive oxygen species (ROS) generation and intrinsic apoptotic pathway. In temozolomide resistance glioblastoma, nZn-CuO NPs disturb cell growth and sphere formation by inhibiting AKT and ERK1/2 activation.
nZn-CuO NPs possess the potential to be developed as a novel anti-tumor agent, especially to treat temozolomide resistance glioblastoma.
评估掺锌氧化铜纳米复合材料（nZn-CuO NPs）对神经胶质瘤治疗的影响。
通过超声化学法合成 nZn-CuO NPs，并在体外和体内研究其抗肿瘤作用及其潜在的分子机制。
nZn-CuO NPs 处理后，分裂癌细胞的增殖明显受到抑制，但正常细胞的毒性较小。体内研究表明，nZn-CuO NPs 呈剂量依赖性抑制肿瘤生长。进一步的研究发现，nZn-CuO NPs 通过触发细胞活性氧（ROS）的产生和内在的凋亡途径来抑制肿瘤生长。在替莫唑胺耐药的神经胶质瘤中，nZn-CuO NPs 通过抑制 AKT 和 ERK1/2 的激活来干扰细胞生长和球体形成。
nZn-CuO NPs 具有作为新型抗肿瘤药物开发的潜力，特别是用于治疗替莫唑胺耐药的神经胶质瘤。
